immunAware ApS – Trademark Portfolio

Entity Type: 66

immunAware ApS holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EASYMERS.

Agern Alle 1

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EASYMERS
EASYMERS
Registered 2021

Trademark Classifications

immunAware ApS's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does immunAware ApS have?

immunAware ApS has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does immunAware ApS file in?

immunAware ApS files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are immunAware ApS's most well-known trademarks?

immunAware ApS's registered trademark portfolio includes well-known marks such as EASYMERS. These are among 1 currently registered trademark in the portfolio.

What is immunAware ApS's trademark registration success rate?

immunAware ApS has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.